Article
Dermatology
Ryota Tanaka, Yuki Ichimura, Noriko Kubota, Risa Konishi, Yoshiyuki Nakamura, Seiya Mizuno, Satoru Takahashi, Manabu Fujimoto, Toshifumi Nomura, Naoko Okiyama
Summary: This study aimed to elucidate the regulatory role of LCs through the PD-1/PD-L1 axis and found that LCs disrupt the exacerbation of psoriasis through PD-L1.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Savannah D. Neu, Anna Strzepa, Dustin Martin, Mary G. Sorci-Thomas, Kirkwood A. Pritchard, Bonnie N. Dittel
Summary: This study found that myeloperoxidase inhibition can alleviate the severity of plaque psoriasis in mice. These findings support the role of oxidative damage in psoriasis pathology and suggest potential new therapeutic avenues for further exploration.
Article
Biochemistry & Molecular Biology
So-Eun Son, Jung-Min Koh, Dong-Soon Im
Summary: This study investigated the role of FFA4 in the treatment of psoriasis. The activation of FFA4 was found to improve imiquimod-induced psoriasis, and the suppression of T(H)17 cell differentiation may contribute to its efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Luise Victoria Claass, Christoph Schultheiss, Rebekka Scholz, Lisa Paschold, Donjete Simnica, Volker Heinemann, Sebastian Stintzing, Mascha Binder
Summary: The two most common antibody targeting principles in oncology are direct antitumor effects and the release of antitumor T cell immunity through immune checkpoint blockade. This study confirms that the targeting of checkpoint molecules on tumor cells can also lead to direct tumor cell killing. It also identifies PD-L1 position 88 as a hotspot residue that critically regulates PD-L1 cell surface expression in the context of immune checkpoint blockade.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Prashantkumar K. Parmar, Nisha Sharma, Shaheen Wasil Kabeer, Aastha Rohit, Arvind K. Bansal
Summary: The study developed a nanocrystal-based gel of apremilast for enhanced anti-psoriatic efficacy. Results showed that the gel could improve psoriatic skin features, decrease biochemical markers, and alleviate inflammation.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Biochemical Research Methods
Honglin Jia, Tao Liu, Qunfang Yang, Haiping Zheng, Shixiang Fu, Jiahui Hong, Zechen Zhou, Qingshan Huang, Zhaowei Zhang, Haigang Zhang, Xiaohong Chen, Renshan Sun, Wenjun Shan
Summary: Psoriasis is a chronic inflammatory disease caused by the dysregulation of cutaneous immune homeostasis. In this study, tumor-derived exosomes carrying pristimerin were used as a nanoplatform for the targeted treatment of inflammatory skin disorders. The PD-L1-positive exosomes carrying pristimerin showed significant anti-inflammatory effects in both in vitro and in vivo models of psoriasis.
BIOCONJUGATE CHEMISTRY
(2023)
Article
Medicine, General & Internal
Michal Adamczyk, Joanna Bartosinska, Dorota Raczkiewicz, Anna Michalak-Stoma, Dorota Krasowska
Summary: The PD-1 receptor and its ligands, PD-L1 and PD-L2, are involved in immune tolerance and prevention of immune-mediated diseases. This study found lower levels of PD-1 and PD-L1 expression in psoriatic patients compared to healthy individuals. Biologic therapy increased PD-L1 expression and decreased PD-1 expression. The disruption of the PD-1/PD-L1 pathway in psoriasis suggests its importance in disease development, and biologic drugs may reverse these abnormalities.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Youliang Zhao, Changfu Hao, Meng Li, Yaqian Qu, Yonghua Guo, Xuedan Deng, Huifang Si, Wu Yao
Summary: This study demonstrates the potential value of immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, in the treatment of silica-induced pulmonary fibrosis. The findings suggest that these inhibitors can modulate immune system disruption caused by silica exposure and provide new ideas for the treatment of fibrosis-related diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, Rongrong Zhou
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by offering long-lasting responses and survival benefits. However, response rates vary among individuals and cancer types, leading to the proposal of dual ICI combination therapy. TIGIT, an inhibitory receptor associated with T-cell exhaustion, has diverse immunosuppressive effects and can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have shown potential benefits, and clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition. Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising approach to improve outcomes for cancer patients treated with ICIs.
Article
Immunology
Pornpimon Yuti, Yupanun Wutti-in, Nunghathai Sawasdee, Katesara Kongkhla, Nattaporn Phanthaphol, Kornkan Choomee, Thaweesak Chieochansin, Aussara Panya, Mutita Junking, Pa-thai Yenchitsomanus, Jatuporn Sujjitjoon
Summary: Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells has shown promising results in the treatment of B-ALL and DLBCL. However, the efficacy in aggressive B cell lymphomas is limited due to poor T cell function caused by the interaction between PD-L1 on BCL cells and PD-1 receptor on T cells. To overcome this, researchers have generated anti-CD19-CAR5-T cells that secrete anti-PD-L1 scFv, which has shown improved antitumor efficiency against CD19+/PD-L1high tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Singaravel Vijayapoopathi, Rajalakshmi Ramamoorthy, Jayaprakash Meganathan, Ananthi Kalaiyazhagan, Sridharan Bhuvarahamurthy, Bhuvarahamurthy Venugopal
Summary: Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes, resulting in skin thickening, scaling, and erythema. Conventional therapies have limitations and potential adverse effects, leading researchers to explore nutraceuticals as alternative options. A study using natural compounds like cannabidiol, myo-inositol, eicosapentaenoic acid, and krill oil in an induced psoriasis mice model shows promising efficacy, especially with the combination of krill oil, cannabidiol, and myo-inositol.
CHEMICAL BIOLOGY & DRUG DESIGN
(2023)
Article
Pharmacology & Pharmacy
Tawit Suriyo, Mayuree Fuangthong, Charlermchai Artpradit, Teerapat Ungtrakul, Thaniya Sricharunrat, Fatma Taha, Jutamaad Satayavivad
Summary: The PD-L1/PD-1 axis inhibits T-cell-mediated immune response in intrahepatic cholangiocarcinoma (CCA), leading to immune evasion. Using an anti-PD-1 antibody may be a potential therapeutic strategy, but further research is needed for validation.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ling Liang, Wen Min Fei, Ze Qiang Zhao, Yu Ying Hao, Chao Zhang, Yong Cui, Xin Dong Guo
Summary: The study showed that pretreatment with microneedles followed by application of calcipotriol had a better therapeutic effect on psoriasis, indicating the potential of microneedles in improving imiquimod-induced psoriasis-like dermatitis in future clinical applications.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Article
Immunology
Xiang Gao, Wei Li, Fahim Syed, Fang Yuan, Ping Li, Qigui Yu
Summary: In traumatic brain injury, PD-L1(+) reactive astrocytes play a crucial role in controlling neuroimmune and neuroinflammatory responses, by inhibiting the activity of brain-infiltrating PD-1(+) immune cells and regulating the astrocyte reactions to prevent excessive immune and inflammatory responses to TBI.
JOURNAL OF NEUROINFLAMMATION
(2022)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.